Rat Dopamine Receptor D2 (DRD2) CLIA Kit
643.5€ (96 tests)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Rat Dopamine Receptor D2 (DRD2) CLIA Kit
category
CLIA Kits
provider
Abbexa
reference
abx196913
tested applications
CLIA
Description
Rat Dopamine Receptor D2 (DRD2) Chemiluminescent Immunoassay (CLIA) Kit is a Chemiluminescent Immunoassay (CLIA) kit against Dopamine Receptor D2 (DRD2).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | CLIA Kits |
| Immunogen Target | Dopamine Receptor D2 (DRD2) |
| Reactivity | Rat |
| Detection Method | Chemiluminescent |
| Assay Data | Quantitative |
| Assay Type | Sandwich |
| Test Range | 0.31 mU/ml - 20 mU/ml |
| Sensitivity | 0.19 mU/ml |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Size 1 | 96 tests |
| Form | Lyophilized |
| Tested Applications | CLIA |
| Sample Type | Serum, plasma and other biological fluids. |
| Availability | Shipped within 5-12 working days. |
| Storage | Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual. |
| Dry Ice | No |
| Alias | DRD2,D2A,D2B,dopamine D2 receptor,dopamine receptor 2,D2 receptor,D2R,D2DR |
| Background | CLIA Kits DRD2 |
| Status | RUO |
| Note | The validity for this kit is 6 months. This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein. |
Descripción
DRD2 is a G protein-coupled receptor belonging to the D2-like receptor family and is highly expressed in the striatum, substantia nigra, and hypothalamus, where it regulates motor control, reward processing, and endocrine function. DRD2 primarily couples to Gi/o proteins, which inhibit adenylate cyclase, reducing cyclic AMP (cAMP) levels and modulating downstream signaling pathways. It exists in two isoforms: the short form (D2S), which functions presynaptically to inhibit dopamine release, and the long form (D2L), which mediates postsynaptic signaling. DRD2 plays a key role in motor control, and its dysfunction is closely linked to Parkinson’s disease, where loss of dopaminergic neurons leads to motor deficits. In neuropsychiatric disorders, DRD2 dysregulation contributes to schizophrenia, bipolar disorder, and drug addiction, where abnormal dopamine signaling disrupts cognition, behavior, and reward mechanisms. Antipsychotic drugs primarily target DRD2 to alleviate symptoms of psychosis by blocking receptor activity. DRD2 also regulates prolactin secretion from the pituitary gland, and its antagonism can cause hyperprolactinemia. Beyond the CNS, DRD2 influences cardiovascular and gastrointestinal function. Given its central role in motor control, reward signaling, and neuropsychiatric disorders, DRD2 remains a critical therapeutic target for Parkinson’s disease, schizophrenia, and substance abuse.
Related Products
Human D2R/DRD2 (Dopamine Receptor D2) ELISA Kit
Ver Producto
DRD2 antibody
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Ver Producto